DMARDs | Docwire News

DMARDs

Investigating the Effects of DMARDs on Sarcopenia

Patrick DalyRheumatoid Arthritis | April 7, 2023

Sarcopenia is a common comorbidity in patients with rheumatoid arthritis (RA) involving muscle mass and quality ...

Could Patients’ Expectations Impact Clinical Response to DMARDs in Rheumatoid Arthritis?

Kaitlyn D’OnofrioRheumatoid Arthritis | April 7, 2023

A study observed a correlation between patients’ expectations toward newly induced disease-modifying antirheumatic ...

Disease Activity, DMARDs May Affect COVID-19 Death Risk in Patients With Rheumatic Disease

Kaitlyn D’OnofrioCOVID-19 | April 6, 2023

In addition to known risk factors, including older age and certain comorbidities, disease activity and specific ...

Rheum Round-up: Abatacept vs. Other bDMARDs in RA, OA and Discrimination, and more

Kaitlyn D’OnofrioRheumatology | February 19, 2021

How Does Abatacept Compare To Other bDMARDs in Rheumatoid Arthritis Treatment? ...

Which Patients With Rheumatoid Arthritis Are More Likely to Experience Multiple Biologic Failures?

Kaitlyn D’OnofrioRheumatoid Arthritis | April 7, 2023

A study examined factors associated with multiple failures to biologic disease-modifying antirheumatic drugs (bDMARDs) ...

Healthcare Visits, DMARD Treatment Both Interrupted for Autoimmune Rheumatic Patients During COVID-19

Kaitlyn D’OnofrioRheumatoid Arthritis | April 7, 2023

The COVID-19 pandemic impacted virtually all areas of health care, whether it be access to medication, conversions to ...

Do Autoimmune Diseases Impact COVID-19 Outcomes?

Kaitlyn D’OnofrioCOVID-19 | April 25, 2023

Patients with autoimmune diseases may be at a greater risk for COVID-19, possibly due to glucocorticoid use, while ...

PTSD, Anxiety, Depression Increase RA Medication Discontinuation Risk

Kaitlyn D’OnofrioDepression | April 25, 2023

Veterans with posttraumatic stress disorder (PTSD), anxiety, and depression on medication for rheumatoid arthritis (RA) ...

Move Over, Methotrexate: Could Upadacitinib Be Rheumatoid Arthritis’ New Shining Star?

Kaitlyn D’OnofrioRheumatoid Arthritis | April 7, 2023

Methotrexate is one of the most common drugs used to treat rheumatoid arthritis (RA). When used early, disease-modifying ...

Low-dose Glucocorticoids Plus Methotrexate and Hydroxychloroquine Effective in Early RA

Kaitlyn D’OnofrioRheumatoid Arthritis | April 12, 2023

Glucocorticoids have been used in rheumatoid arthritis (RA) for decades and in recent years have been used as ...

What Does COVID-19 Look Like in Patients Taking Immunosuppressive Agents?

Kaitlyn D’OnofrioCOVID-19 | April 6, 2023

Many unknowns remain about COVID-19, with researchers working to discover good information. One area of exploration is ...

Rheum Round-up: Phase 3 Baricitinib COVID-19 Trial Kicks Off, Digital RA Monitoring, and more

Kaitlyn D’OnofrioRheumatology | June 19, 2020

Here are the top stories recently covered by DocWire News in the Rheumatology section. In this edition, read about the ...

NSAIDs, DMARDs May Not Increase Hospitalization Risk in COVID-19 Patients

Kaitlyn D’OnofrioCOVID-19 | April 25, 2023

The use of non-steroidal anti-inflammatory drugs (NSAIDs) and conventional disease-modifying antirheumatic drugs ...

Sarilumab, Alone or in Combination with Conventional Synthetic DMARDs, Safe and Effective for Most RA Patients

Kaitlyn D’OnofrioRheumatoid Arthritis | April 7, 2023

Researchers recently assessed the safety and efficacy of sarilumab either as a monotherapy or in combination with ...

Rheum Round-up: Five RA Drugs Compared, Two THA Approaches, and more

Kaitlyn D’OnofrioRheumatology | June 5, 2020

Here are the top stories recently covered by DocWire News in the Rheumatology section. In this edition, read about a ...

csDMARDs versus TNF-inhibitors: Which Should Be Tapered First for DMARD-free Remission in RA?

Kaitlyn D’OnofrioRheumatoid Arthritis | April 12, 2023

A study evaluated two strategies for gradual tapering toward disease-modifying antirheumatic drug- (DMARD) free ...

Do Outcomes Largely Differ in Very Early Rheumatoid Arthritis Treated with First-line Etanercept Plus Methotrexate versus Treat-to-Target Methotrexate?

Kaitlyn D’OnofrioRheumatoid Arthritis | April 25, 2023

A study compared superiority outcomes in very early rheumatoid arthritis (RA) treated with first-line etanercept plus ...

‘Timing Matters’: Treat Juvenile Idiopathic Arthritis Aggressively and Early with bDMARDs, Researchers Say

Kaitlyn D’OnofrioRheumatology | September 12, 2023

A recent study concluded that “timing matters” and that early, aggressive treatment trumps delayed, conservative ...

Upadacitinib Improves QOL in RA Patients when Biologics Fail

Kaitlyn D’OnofrioRheumatoid Arthritis | April 7, 2023

A new study compared the impact of upadacitinib versus placebo on patient-reported outcomes (PROs) and quality of life ...

Do JIA Patients Have An Increased Cancer Risk?

Kaitlyn D’OnofrioOncology | September 12, 2023

A newly published study examined trends in the risk of cancer among patients with juvenile idiopathic arthritis (JIA). ...